141 related articles for article (PubMed ID: 38420134)
1. The cost of human papillomavirus vaccination delivery at the administrative and health facility levels in the Philippines.
Aldaba JG; Llave CL; Uy MEV; Tejano KP; Aquino MRC; Antonio P Catalig M; Sy ADR; Valverde HA; Mooney J; Slavkovsky R
Vaccine X; 2024 Mar; 17():100459. PubMed ID: 38420134
[TBL] [Abstract][Full Text] [Related]
2. Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
Mvundura M; Slavkovsky R; Debellut F; Naddumba T; Bayeh A; Ndiaye C; Anena J; Vodicka E; Diop A; Gamage D; Musanabaganwa C; Tatkan G; Driwale A; Zelalem M; Badiane O; Ginige S; Hamilton E; Sibomana H; Lakew Y; Uwinkindi F; Dhufera A; Ampeire I; Kumar S; Lamontagne DS
Vaccine; 2023 Nov; 41(49):7435-7443. PubMed ID: 37949752
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia.
Simuyemba MC; Chama-Chiliba CM; Chompolola A; Sinyangwe A; Bchir A; Asiimwe G; Chibwesha C; Masiye F
BMC Infect Dis; 2024 Apr; 24(1):369. PubMed ID: 38565994
[TBL] [Abstract][Full Text] [Related]
4. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
Brennan T; Hidle A; Doshi RH; An Q; Loharikar A; Casey R; Badiane O; Ndiaye A; Diallo A; Loko Roka J; Mejia N; Abimbola T
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A77-A84. PubMed ID: 34955325
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus (HPV) vaccination program in Sri Lanka: Ongoing costs and operational context of a routinized program.
Debellut F; Gamage D; Kumar S; Wickramasinghe S; Ruwanpathirana T; Kariyawasam M; Perera CS; Ginige S; Cooray N; Pecenka C; Slavkovsky R; Scott LaMontagne D; Mvundura M
Vaccine X; 2024 Mar; 17():100456. PubMed ID: 38379668
[TBL] [Abstract][Full Text] [Related]
6. Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
Hidle A; Brennan T; Garon J; An Q; Loharikar A; Marembo J; Manangazira P; Mejia N; Abimbola T
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A67-A76. PubMed ID: 35181152
[TBL] [Abstract][Full Text] [Related]
7. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
Botwright S; Holroyd T; Nanda S; Bloem P; Griffiths UK; Sidibe A; Hutubessy RCW
PLoS One; 2017; 12(10):e0182663. PubMed ID: 29016596
[TBL] [Abstract][Full Text] [Related]
8. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
Slavkovsky R; Callen E; Pecenka C; Mvundura M
Vaccine; 2024 Feb; 42(6):1200-1210. PubMed ID: 38302338
[TBL] [Abstract][Full Text] [Related]
9. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
10. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
[TBL] [Abstract][Full Text] [Related]
11. Assessing the incremental costs and savings of introducing electronic immunization registries and stock management systems: evidence from the better immunization data initiative in Tanzania and Zambia.
Mvundura M; Di Giorgio L; Vodicka E; Kindoli R; Zulu C
Pan Afr Med J; 2020; 35(Suppl 1):11. PubMed ID: 32373262
[TBL] [Abstract][Full Text] [Related]
12. An Evaluation of the Cost of Human Papilloma Virus (HPV) Vaccine Delivery In Zambia.
Simuyemba MC; Chama-Chiliba CM; Chompola A; Sinyangwe A; Bchir A; Asiimwe G; Masiye F; Chibwesha C
Res Sq; 2023 May; ():. PubMed ID: 37398262
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool.
Levin A; Yuma S; Swai E; Morgan W; Gauvreau CL; Broutet N; Yeung KHT; Hutubessy R
BMC Med; 2022 Nov; 20(1):384. PubMed ID: 36316680
[TBL] [Abstract][Full Text] [Related]
14. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
Baral R; Levin A; Odero C; Pecenka C; Tanko Bawa J; Antwi-Agyei KO; Amponsa-Achaino K; Chisema MN; Eddah Jalango R; Mkisi R; Gordon S; Morgan W; Muhib F
Vaccine; 2023 Feb; 41(8):1496-1502. PubMed ID: 36710234
[TBL] [Abstract][Full Text] [Related]
15. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
[TBL] [Abstract][Full Text] [Related]
16. Financial cost analysis of a strategy to improve the quality of administrative vaccination data in Uganda.
Ward K; Mugenyi K; MacNeil A; Luzze H; Kyozira C; Kisakye A; Matseketse D; Newall AT; Heywood AE; Bloland P; Pallas SW
Vaccine; 2020 Jan; 38(5):1105-1113. PubMed ID: 31767466
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
18. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
[TBL] [Abstract][Full Text] [Related]
19. Incorporating economies of scale in the cost estimation in economic evaluation of PCV and HPV vaccination programmes in the Philippines: a game changer?
Suwanthawornkul T; Praditsitthikorn N; Kulpeng W; Haasis MA; Guerrero AM; Teerawattananon Y
Cost Eff Resour Alloc; 2018; 16():7. PubMed ID: 29483848
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
